AstraZeneca's Imfinzi combination fails advanced lung cancer study

AstraZeneca said on Wednesday a combination treatment including its lung cancer drug Imfinzi failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations.